ODTX insider transaction filings
Odyssey Therapeutics, Inc. — 15 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-05-13. Screen ODTX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-13 | 4 | TPG GP A, LLC COULTER JAMES G WINKELRIED JON | Other (J): 423,111 · Other (J): 2,351 @ $18 · Conversion (C): 1,880,497 · Purchase (P): 1,388,889 @ $18 · Other (J): 423,111 (derivative) · Conversion (C): 18,272,789 (derivative) | EDGAR |
| 2026-05-12 | 4 | Dimension Capital II, L.P. — Director | Conversion (C): 1,709,543 · Purchase (P): 1,111,111 @ $18 · Conversion (C): 16,611,626 (derivative) | EDGAR |
| 2026-05-11 | 4 | Haas Jason — Chief Financial Officer | Purchase (P): 1,000 @ $20 | EDGAR |
| 2026-05-11 | 4 | Li Nan (LN) — Director | Conversion (C): 1,709,543 · Purchase (P): 1,111,111 @ $18 · Conversion (C): 16,611,626 (derivative) | EDGAR |
| 2026-05-11 | 4 | Chu Shelley — Director | Purchase (P): 11,111 @ $18 | EDGAR |
| 2026-05-11 | 4 | Dales Natalie — See Remarks | Grant/award (A): 79,773 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Glick Gary D — See Remarks, Director | Conversion (C): 27,386 · Conversion (C): 100,000 (derivative) · Conversion (C): 166,116 (derivative) · Grant/award (A): 884,450 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Opipari Anthony W. — See Remarks | Conversion (C): 6,965 · Option exercise (M): 541 · Tax withholding (F): 4 @ $18 · Conversion (C): 18,531 (derivative) · Conversion (C): 11,083 (derivative) · Conversion (C): 20,000 (derivative) · +4 more | EDGAR |
| 2026-05-11 | 4 | Todd Collin M — See Remarks | Grant/award (A): 93,904 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Odegard Valerie — Director | Grant/award (A): 27,393 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Tatsis Ourania — Director | Grant/award (A): 27,393 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | SR ONE CAPITAL MANAGEMENT, LLC — 10% owner George Simeon — 10% owner | Conversion (C): 474,048 · Conversion (C): 139,366 · Conversion (C): 59,692 · Conversion (C): 61,762 · Conversion (C): 683,817 · Option exercise/expiry (X): 191,541 · +30 more | EDGAR |
| 2026-05-11 | 4 | Walbert Timothy P — Director | Grant/award (A): 27,393 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | LEIDEN JEFFREY M — Director | Purchase (P): 5,000 @ $20 · Conversion (C): 28,698 · Option exercise (M): 2,963 · Tax withholding (F): 17 @ $18 · Conversion (C): 79,166 (derivative) · Conversion (C): 100,000 (derivative) · +3 more | EDGAR |
| 2026-05-11 | 4 | SMITH IAN F — Director | Grant/award (A): 27,393 (derivative) @ $0 | EDGAR |
Recent 8-K events — Odyssey Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ODTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →